NasdaqGM - Nasdaq Real Time Price USD

Sionna Therapeutics, Inc. (SION)

Compare

11.07

+1.07

+(10.70%)

At close: April 17 at 4:00:00 PM EDT

11.07

0.00

(0.00%)

After hours: April 17 at 4:00:09 PM EDT

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 On track to initiate NBD1 Phase 2a proof-of-concept trial in combination with SOC in CF patients and combination MAD trials of an NBD1 stabilizer with a complementary modulator in healthy volunteers in the second half of 2025, with topline data for both anticipa

GlobeNewswire 28 days ago

SION
+10.70%
Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month

We recently published a list of Top 10 Insider Purchases Last Month. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the U.S. economy? What’s next on President Trump’s geopolitical […]

Insider Monkey last month

SION
+10.70%
Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently?

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks with at least $20 million in insider spending recently. As the stock market navigates a complex environment shaped […]

Insider Monkey last month

SION
+10.70%
Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump took office, the stock market has […]

Insider Monkey last month

SION
+10.70%
Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market

The company's IPO follows a $182m Series C funding round last year.

Pharmaceutical Technology last month

SION
+10.70%
VRTX

ABBV
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET. A live webcast o

GlobeNewswire last month

SION
+10.70%
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year?

We recently published a list of 10 Stocks Insiders Are Buying This Year. In this article, we are going to take a look at where Sionna Therapeutics, Inc. (NASDAQ:SION) stands against other stocks that insiders are buying this year. Even though this is just the beginning of the year, we thought it might be interesting […]

Insider Monkey last month

SION
+10.70%
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the closing of its upsized initial public offering of 12,176,467 shares of its common stock at a public offering price of $18.00 per share

GlobeNewswire 2 months ago

SION
+10.70%
Sionna Therapeutics Prices Upsized Initial Public Offering

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the pricing of its upsized initial public offering of 10,588,233 shares of its common stock at a public offering price of $18.00 per share.

GlobeNewswire 2 months ago

SION
+10.70%
Vertex challenger Sionna prices $191M IPO

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.

BioPharma Dive 2 months ago

SION
+10.70%

Performance Overview

Return	SION	S&P 500 (^GSPC)
YTD	-55.72%	-10.18%
1-Year	-55.72%	+5.19%
3-Year	-55.72%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month

Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently?

Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently

Sionna Therapeutics’ IPO: A strategic shift in the cystic fibrosis market

Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference

Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year?

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sionna Therapeutics Prices Upsized Initial Public Offering

Vertex challenger Sionna prices $191M IPO

Performance Overview